-+ 0.00%
-+ 0.00%
-+ 0.00%

3 Defensive Dividend Stocks for Fed Uncertainty Including McCormick and UnitedHealth

Simply Wall St·09/14/2026 15:28:23
Listen to the news

With traders fixated on whether the Fed moves 25 bps or holds fire, higher August CPI and tense rate odds are pushing money toward large U.S. dividend stocks that offer fewer surprises. Cash still needs a home, even when policy is up in the air, and hesitating can mean missing solid opportunities. This article walks through three large-cap defensive dividend stocks exposed to the current Fed narrative and explains why each deserves a closer look.

The three stocks covered next are a sample from a larger group, and the full screen surfaced 20 more large-cap U.S. defensive dividend companies with equally compelling stories that are not covered here. To see the wider field, head straight to the Large-Cap U.S. Defensive Dividend Stocks screener to identify, analyze, and focus on the ideas that fit your portfolio best.

McCormick (MKC)

McCormick sits neatly in the defensive dividend camp, with a consumer staples profile that tends to hold attention when rate headlines get noisy. Its flavor portfolio gives it a different kind of pricing power story than many classic household goods stocks.

McCormick & Company makes herbs, spices, seasoning mixes, condiments, and other flavor products for households and foodservice customers worldwide, with about US$4.4b from its Consumer segment and US$3.0b from Flavor Solutions, and a roughly US$13.9b market cap.

"Growing demand for flavorful, natural, and clean-label foods, combined with increased at-home cooking and a heightened consumer focus on health, continues to underpin premiumization strategies and new product introductions, supporting elevated pricing power and mix benefits that can positively impact net margins."

What really matters for dividend investors now is how one less visible pressure on those margins plays out over the next few years.

That margin squeeze is the real story to unpack, and the full narrative for McCormick lays out how pricing power, capital allocation, and risks could be quietly reshaping the thesis.

NYSE:MKC Revenue & Expenses Breakdown as at Sep 2026
NYSE:MKC Revenue & Expenses Breakdown as at Sep 2026

UnitedHealth Group (UNH)

UnitedHealth Group brings a large, diversified healthcare footprint to this defensive dividend screen. It combines insurance and services that tend to hold investor attention when rate expectations and CPI surprises put pressure on more cyclical sectors.

UnitedHealth Group runs UnitedHealthcare insurance plans alongside Optum Health, Optum Insight, and Optum Rx. It generates about US$346.5b from UnitedHealthcare, US$155.2b from Optum Rx, US$100.0b from Optum Health, and US$19.7b from Optum Insight, with a market value near US$340.3b.

"The company is addressing unanticipated changes in Medicare membership profiles which impacted 2025 revenue."

What happens to margins if one quiet assumption in that reset does not hold will matter a lot for this stock’s income appeal.

If that assumption is wrong, the full narrative for UnitedHealth Group shows how Medicare shifts, Optum dynamics, and capital use could be quietly reshaping UnitedHealth Group's long term income story.

NYSE:UNH Revenue & Expenses Breakdown as at Sep 2026
NYSE:UNH Revenue & Expenses Breakdown as at Sep 2026

CVS Health (CVS)

CVS Health gives this defensive dividend screen a pure-play U.S. healthcare angle by combining insurance, pharmacy services, and retail drugstores into one integrated platform that can appeal to investors looking for recurring cash flows as rate headlines keep shifting.

CVS Health runs an integrated U.S. health solutions model across Health Services, Health Care Benefits, and Pharmacy & Consumer Wellness, generating about US$200.5b, US$143.8b, and US$139.7b respectively, plus a small Corporate/Other line, and carries a roughly US$121.1b market value.

"CVS Health has just faced a stock decline of about 10% after its preliminary Q3 earnings miss, which made the entire market aware."

What really matters now is how one unresolved pressure inside that integrated care model ultimately feeds through to earnings resilience and dividend comfort.

If that pressure point matters to your income plan, read the full narrative for CVS Health to see what might be masking CVS Health’s longer term dividend potential.

NYSE:CVS Earnings & Revenue History as at Sep 2026
NYSE:CVS Earnings & Revenue History as at Sep 2026

Seeking Alternatives Before Momentum Flies

Fresh opportunities move fast. Breakout stories can be caught early or missed completely as information decays and prices start flying. Scan under the radar for now and evaluate opportunities promptly.

  • Target durable income streams while they are still offering compelling yields by reviewing the 6 dividend fortresses and assessing which payers fit your long term plan.
  • Track developments in the AI buildout by scanning the 89 AI infrastructure stocks and identifying which enablers show real earnings power as conditions evolve.
  • Consider the electrification buildout by assessing the 39 power grid technology and infrastructure stocks and reviewing which operators may be positioned to benefit if spending continues to flow into grid upgrades.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.